These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9127302)

  • 41. Review of AAPM Task Group No. 43 recommendations on interstitial brachytherapy sources dosimetry. American Association of Physicists in Medicine.
    Saw CB; Meigooni AS; Nath R
    Med Dosim; 1998; 23(4):259-63. PubMed ID: 9863722
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the dose distribution for prostate implants using various 125I and 103Pd sources.
    Meigooni AS; Luerman CM; Sowards KT
    Med Phys; 2009 Apr; 36(4):1452-8. PubMed ID: 19472652
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dosimetric characteristics of the bests double-wall 103Pd brachytherapy source.
    Meigooni AS; Bharucha Z; Yoe-Sein M; Sowards K
    Med Phys; 2001 Dec; 28(12):2568-75. PubMed ID: 11797962
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of new GAFCHROMIC EBT film for 125I seed dosimetry in Solid Water phantom.
    Chiu-Tsao ST; Medich D; Munro J
    Med Phys; 2008 Aug; 35(8):3787-99. PubMed ID: 18777938
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative study of permanent interstitial prostate brachytherapy post-implant evaluation among seven Italian institutes.
    Mangili P; Stea L; Cattani F; Lappi S; Giglioli F; Calamia E; Ziglio F; Martinelli R; Longobardi B
    Radiother Oncol; 2004 Apr; 71(1):13-21. PubMed ID: 15066291
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phantom size in brachytherapy source dosimetric studies.
    Pérez-Calatayud J; Granero D; Ballester F
    Med Phys; 2004 Jul; 31(7):2075-81. PubMed ID: 15305460
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dosimetric parameters for three low-energy brachytherapy sources using the Monte Carlo N-particle code.
    DeMarco JJ; Hugo G; Solberg TD
    Med Phys; 2002 May; 29(5):662-8. PubMed ID: 12033560
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Report on the dosimetry of a new design 125Iodine brachytherapy source.
    Wallace RE; Fan JJ
    Med Phys; 1999 Sep; 26(9):1925-31. PubMed ID: 10505882
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry: implications for dose specification and prescription.
    Williamson JF; Coursey BM; DeWerd LA; Hanson WF; Nath R; Rivard MJ; Ibbott G
    Med Phys; 2000 Apr; 27(4):634-42. PubMed ID: 10798683
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dosimetric comparison of four new design 103Pd brachytherapy sources: optimal design using silver and copper rod cores.
    Hosseini SH; Sadeghi M; Ataeinia V
    Med Phys; 2009 Jul; 36(7):3080-5. PubMed ID: 19673207
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A nomograph for permanent implants of palladium-103 seeds.
    Anderson LL; Moni JV; Harrison LB
    Int J Radiat Oncol Biol Phys; 1993 Sep; 27(1):129-35. PubMed ID: 8365933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Calculated dosimetric parameters of the IoGold 125I source model 3631-A.
    Wierzbicki JG; Rivard MJ; Waid DS; Arterbery VE
    Med Phys; 1998 Nov; 25(11):2197-9. PubMed ID: 9829245
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MCPI: a sub-minute Monte Carlo dose calculation engine for prostate implants.
    Chibani O; Williamson JF
    Med Phys; 2005 Dec; 32(12):3688-98. PubMed ID: 16475768
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Isotope choice and the effect of edema on prostate brachytherapy dosimetry.
    Butler WM; Merrick GS; Dorsey AT; Lief JH
    Med Phys; 2000 May; 27(5):1067-75. PubMed ID: 10841411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of a rat solid tumor model for continuous low-dose-rate irradiation studies using 125I and 103Pd sources.
    Nath R; Bongiorni P; Chen Z; Gragnano J; Rockwell S
    Brachytherapy; 2004; 3(3):159-72. PubMed ID: 15533809
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Experimental and theoretical determination of dosimetric characteristics of IsoAid ADVANTAGE 125I brachytherapy source.
    Meigooni AS; Hayes JL; Zhang H; Sowards K
    Med Phys; 2002 Sep; 29(9):2152-8. PubMed ID: 12349937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dosimetric characterization of a new design 103 palladium brachytherapy source.
    Wallace RE; Fan JJ
    Med Phys; 1999 Nov; 26(11):2465-70. PubMed ID: 10587234
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monte Carlo calculated TG-43 dosimetry parameters for the SeedLink 125Iodine brachytherapy system.
    Medich DC; Munro JJ
    Med Phys; 2003 Sep; 30(9):2503-8. PubMed ID: 14528972
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COMS eye plaque brachytherapy dosimetry simulations for 103Pd, 125I, and 131Cs.
    Melhus CS; Rivard MJ
    Med Phys; 2008 Jul; 35(7):3364-71. PubMed ID: 18697560
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dosimetric characteristic of a new 125I brachytherapy source.
    Sadeghi M; Khanmohammadi Z
    Radiat Prot Dosimetry; 2011 Nov; 147(3):451-6. PubMed ID: 21233096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.